Live feed08:00:00·24dPRReleasevia QuantisnowIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trialByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
